Foresite Capital and Director Tananbaum Invest $10.6M in Alumis Stock
summarizeSummary
This Schedule 13D/A filing reveals that Foresite Capital, a major institutional shareholder, and James B. Tananbaum, a director of Alumis Inc. and managing member of Foresite entities, have significantly increased their beneficial ownership. The group acquired approximately $3.6 million in open market purchases in November 2025 and an additional $7.0 million in the company's follow-on offering on January 8, 2026. These substantial investments, totaling around $10.6 million, demonstrate strong conviction from a key investor and insider, particularly following a period of dilution. The participation in the follow-on offering at $17.00 per share, compared to the current stock price of $21.08, suggests confidence in the company's valuation and future prospects.
check_boxKey Events
-
Significant Insider/Institutional Purchases
Foresite Capital and director James B. Tananbaum acquired approximately $10.6 million worth of Alumis Inc. common stock.
-
Follow-on Offering Participation
The group purchased $7.0 million in shares at $17.00 per share as part of the company's January 8, 2026 follow-on offering.
-
Open Market Acquisitions
An additional $3.6 million in shares were acquired through open market purchases in November 2025.
-
Increased Beneficial Ownership
The reporting persons collectively hold 14.1% of Alumis Inc.'s common stock.
auto_awesomeAnalysis
This Schedule 13D/A filing reveals that Foresite Capital, a major institutional shareholder, and James B. Tananbaum, a director of Alumis Inc. and managing member of Foresite entities, have significantly increased their beneficial ownership. The group acquired approximately $3.6 million in open market purchases in November 2025 and an additional $7.0 million in the company's follow-on offering on January 8, 2026. These substantial investments, totaling around $10.6 million, demonstrate strong conviction from a key investor and insider, particularly following a period of dilution. The participation in the follow-on offering at $17.00 per share, compared to the current stock price of $21.08, suggests confidence in the company's valuation and future prospects.
在该文件披露时,ALMS的交易价格为$21.08,交易所为NASDAQ,所属行业为Life Sciences,市值约为$25.7亿。 52周交易区间为$2.76至$22.30。 这份文件被评估为积极市场情绪,重要性评分为8/10。